Combinature Biopharm (NMR Fragment-Based Drug Discovery Business) is Biotechnology in Germany that focus on respective genes business. They cover business area such as Provider, drug discovery platform, novel enzyme, biocatalysis application, parallel, house, customer, library, essential natural compound.
-
Respective Genes
-
Robert-Rössle-Strasse 10
13125 Berlin
Germany
Private
Providerdrug discovery platformnovel enzymebiocatalysis applicationparallelhousecustomerlibraryessential natural compound
* We use standard office opening hours in near Combinature Biopharm (NMR Fragment-Based Drug Discovery Business)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Combinature Biopharm (NMR Fragment-Based Drug Discovery Business) is Biotechnology business from Germany that founded in - ( years old in ), Combinature Biopharm (NMR Fragment-Based Drug Discovery Business) business is focusing on Respective Genes.
Combinature Biopharm (NMR Fragment-Based Drug Discovery Business) headquarter office and corporate office address is located in Robert-Rössle-Strasse 10 13125 Berlin Germany.
Combinature Biopharm (NMR Fragment-Based Drug Discovery Business) was founded in Germany.
In , Combinature Biopharm (NMR Fragment-Based Drug Discovery Business) is currently focus on respective genes sector.
Above is snippet of Google Trends for "respective genes" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Combinature Biopharm (NMR Fragment-Based Drug Discovery Business), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
